GlobeNewswire Inc | Nov 1, 2021 04:02PM EDT

November 01, 2021

PHILADELPHIA, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX), a womens oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, today announced the appointment of Jennifer Minai-Azary as Chief Financial Officer and the prior appointment, in April 2021, of Alex Levit as Chief Legal Officer.

It is an exciting time for the company following our recent debut on Nasdaq and Id like to thank Alex for all of his contributions to help make this happen. Im also pleased to welcome Jennifer Minai-Azary to Contexts leadership team, said Martin Lehr, Chief Executive Officer of Context. Jennifers and Alexs deep biopharma financial and legal expertise, respectively, and their proven leadership skills will be instrumental to Context as we navigate this new chapter for the company and work to deliver on our near- and long-term corporate and clinical milestones.

Ms. Minai-Azary brings more than 20 years of finance and accounting experience to Context. Prior to joining Context, Ms. Minai-Azary served in roles of increasing responsibility at Millendo Therapeutics, culminating in chief financial officer, where she led financial operations, including guiding the companys merger with Tempest Therapeutics, a clinical-stage oncology company. Earlier in her career, Ms. Minai-Azary was director of technical accounting at Parexel and began her career in Ernst & Youngs audit practice. Ms. Minai-Azary holds a Master of Accounting and a Bachelor of Business Administration from the University of Michigan and is a certified public accountant.

Im excited to join Context at this important juncture in the companys growth and I look forward to leading the companys finance organization, said Ms. Minai-Azary. I am eager to help deliver on the companys ongoing commitment to provide patients with more therapeutic options and to drive long-term value for our shareholders.

Mr. Levit is a seasoned legal advisor with nearly two decades of industry experience advising public and private companies. Prior to joining Context, Mr. Levit served as vice president, deputy general counsel and assistant corporate secretary of OptiNose, a publicly held specialty pharmaceutical company. Previously, Mr. Levit was associate general counsel of Teva Pharmaceuticals, a global pharmaceutical company. During his tenures at OptiNose and Teva, Mr. Levit negotiated various in-bound and out-bound licenses, collaborations, and mergers and acquisitions, as well as clinical trial agreements and supply agreements.Earlier in his career, Mr. Levit was an attorney at Reed Smith LLP. Mr. Levit currently sits on the Board of Directors of Strados Labs, a medical device company. Mr. Levit holds a J.D. from Temple University Beasley School of Law and a Bachelor of Arts in Labor & Industrial Relations from Pennsylvania State University, where he graduated from the Schreyer Honors College.

Im inspired by Contexts important mission to address the devastating unmet need in hormone-driven womens cancers, said Mr. Levit. I look forward to collaborating with the Context leadership team and Board to contribute to Contexts growth and future success.

About Context TherapeuticsContext Therapeutics Inc. (Nasdaq: CNTX) is a womens oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Companys robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven womens cancers. The Company is headquartered in Philadelphia, PA. For more information, visit www.contexttherapeutics.com.

Forward-looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as "may," "will," "expect," "anticipate," "plan," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the results of our clinical trials, (ii) the potential benefits of the product candidates, (iii) the likelihood data will support future development, and (iv) the likelihood of obtaining regulatory approval of our product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with theU.S. Securities and Exchange Commission, including the section titled Risk Factors contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Media Contact:Heather Anderson6 Degrees919-827-5539handerson@6degreespr.com